Details

Autor(en) / Beteiligte

• VERGNE, Laurence
• DIAGBOUGA, Serge
• HIEN, Hervé
• ZEKENG, Léopold
• DELAPORTE, Eric
• PEETERS, Martine
• KOUANFACK, Charles
• AGHOKENG, Avelin
• BUTEL, Christelle
• LAURENT, Christian
• NOUMSSI, Nathalie
• TARDY, Michele
• SAWADOGO, Adrien
• DRABO, Joseph

Titel

HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon

Ist Teil von

• Antiviral therapy, 2006-01, Vol.11 (5), p.575-579

Ort / Verlag

London: International Medical Press

Erscheinungsjahr

2006

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n = 1], M41L+T69S [n = 1]), four to non-NRTIs (NNRTIs; V106A/V [n = 1] and V1081 [n = 3]) and two to protease inhibitors (PIs; L33F [n = 2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.